RXRX
Recursion Pharmaceuticals Inc
3.70$
-3.9%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.3% | -2.3% | +21.6% | -19.7% | +79.9% | +49.3% | +23.4% | -11.8% | -7.4% | +1.0% | -7.7% | – | |
| – | -4.2% | +0.3% | +2.5% | +10.5% | +68.7% | +17.1% | -27.5% | -3.5% | -5.9% | -6.5% | -12.2% | – | |
| – | – | – | – | – | – | -196.8% | – | -174.8% | – | -173.1% | – | – | |
| – | +192.3% | +175.3% | -37.1% | +9.1% | -63.9% | +11.2% | +71.9% | -92.3% | +411.9% | -72.8% | +479.6% | – | |
| – | +617.0% | +167.4% | -37.1% | +9.1% | – | -102.6% | -20.1% | -56.1% | -51.2% | -72.8% | +479.6% | – | |
| – | – | – | – | – | -8.1% | -2.6% | +1.8% | +2.1% | +1.9% | +1.9% | +1.9% | – | |
| – | +50.0% | -82.8% | +1,793.4% | -93.7% | -35.4% | +280.9% | +141.0% | +157.4% | -47.5% | -102.6% | -63.5% | – | |
| – | – | -2,358.8% | – | -126.6% | – | -156.1% | – | +439.9% | -34.9% | -202.3% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.